Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOIR: Correction of Hemoglobin and Outcomes In Renal Insufficiency
NCT00211120Phase 4Terminated
- Sponsor
- Johnson & Johnson
- Start
- Mar 2002
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 4, randomised, open-label trial of epoetin alfa in anemia (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Composite of mortality (all cause), myocardial infarction, stroke, and CHF hospitalization. Started Mar 2002; status: terminated.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00211120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00211120.